KOD Kodiak Sciences Inc.
USHealthcareAs of 2026-08-24
Why KOD matters now
Kodiak Sciences Inc. (KOD) is a US stock in Healthcare. The latest InvestLog snapshot shows $37.22 with -2.90% on the session and $2.33B in market capitalization; recent performance reads 1-month +5.00% and YTD +29.26%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-58.2M, and EPS of $-0.94. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.7%.
The latest indexable market news headline is "Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $59.50; recent insider activity includes BORGESON JOHN A. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
19.94
P/S
0.00
EV/EBITDA
-9.45
DCF Value
$0.74
FCF Yield
-7.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-253.8%
ROA
-75.4%
ROIC
-87.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-58.2M | $-0.94 |
| Q4 2025 | $0.00 | $-56.7M | $-1.04 |
| FY 2025 | $0.00 | $-230.0M | $-4.32 |
| Q3 2025 | $0.00 | $-61.5M | $-1.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$63.75
Target (Median)
$59.50
Target Range
$56.00 - $80.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.21
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.